| Name | Title | Contact Details |
|---|
CFHP was established in 1995, by the University Health System, specifically to begin providing health care coverage to the citizens of Bexar and the surrounding seven counties. As the only locally owned and managed, non-profit health plan in the area,
Immunization for Public Health (i4ph) is a Galveston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Carenet Health is a leading provider of healthcare consumer engagement solutions, clinical support, health advocacy and navigation solutions, and 24/7 access to medical care. Our engagement specialists, care coordinators and registered nurses support 1 in 4 Americans (more than 86 million healthcare consumers) on behalf of 250+ of the nation`s premier health plans, providers, health systems and Fortune 500 organizations. Our mission is to drive market-leading consumer engagement outcomes through our proprietary Intelligent Engagement model. Our best-practice solutions are delivered by outstanding teams and backed by clinical capital, data and technology, operational excellence and expertise from outside of healthcare. Every day, our team members guide people to high-quality and cost-effective care, and coach them to close gaps in care and improve their health. For eight consecutive years, Inc. Magazine named Carenet as one of America`s fastest-growing private companies.
Digital Health Information Management provider for Sub-Saharan Africa.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.